A detailed history of Royal Bank Of Canada transactions in Scholar Rock Holding Corp stock. As of the latest transaction made, Royal Bank Of Canada holds 5,000 shares of SRRK stock, worth $152,150. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,000
Previous 219,785 97.73%
Holding current value
$152,150
Previous $3.9 Million 98.95%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$7.84 - $16.79 $1.67 Million - $3.58 Million
-213,343 Reduced 97.07%
6,442 $53,000
Q1 2024

May 15, 2024

BUY
$13.2 - $17.76 $2.67 Million - $3.6 Million
202,479 Added 1169.99%
219,785 $3.9 Million
Q4 2023

Feb 14, 2024

BUY
$6.52 - $20.32 $56,834 - $177,129
8,717 Added 101.49%
17,306 $325,000
Q3 2023

Nov 14, 2023

BUY
$6.02 - $7.76 $30,677 - $39,544
5,096 Added 145.89%
8,589 $60,000
Q2 2023

Aug 14, 2023

BUY
$5.79 - $9.11 $13,305 - $20,934
2,298 Added 192.3%
3,493 $26,000
Q1 2023

May 15, 2023

BUY
$7.36 - $12.72 $8,000 - $13,826
1,087 Added 1006.48%
1,195 $9,000
Q4 2022

Feb 14, 2023

BUY
$7.02 - $9.76 $758 - $1,054
108 New
108 $0
Q2 2022

Aug 15, 2022

SELL
$4.66 - $13.96 $8,085 - $24,220
-1,735 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$11.89 - $24.68 $50,901 - $105,655
-4,281 Reduced 71.16%
1,735 $22,000
Q4 2021

Feb 14, 2022

BUY
$24.14 - $35.18 $89,293 - $130,130
3,699 Added 159.65%
6,016 $149,000
Q3 2021

Nov 15, 2021

BUY
$27.38 - $42.21 $11,499 - $17,728
420 Added 22.14%
2,317 $77,000
Q2 2021

Aug 16, 2021

BUY
$26.34 - $46.62 $49,966 - $88,438
1,897 New
1,897 $55,000

Others Institutions Holding SRRK

About Scholar Rock Holding Corp


  • Ticker SRRK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 51,640,600
  • Market Cap $1.57B
  • Description
  • Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...
More about SRRK
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.